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ABSTRACT
One major impediment to the wider use of deep learning for clinical decision making is the difficulty
of assigning a level of confidence to model predictions. Currently, deep Bayesian neural networks
and sparse Gaussian processes are the main two scalable uncertainty estimation methods. However,
deep Bayesian neural network suffers from lack of expressiveness, and more expressive models
such as deep kernel learning, which is an extension of sparse Gaussian process, captures only the
uncertainty from the higher level latent space. Therefore, the deep learning model under it lacks
interpretability and ignores uncertainty from the raw data. In this paper, we merge features of the deep
Bayesian learning framework with deep kernel learning to leverage the strengths of both methods for
more comprehensive uncertainty estimation. Through a series of experiments on predicting the first
incidence of heart failure, diabetes and depression applied to large-scale electronic medical records, we
demonstrate that our method is better at capturing uncertainty than both Gaussian processes and deep
Bayesian neural networks in terms of indicating data insufficiency and distinguishing true positive and
false positive predictions, with a comparable generalisation performance. Furthermore, by assessing
the accuracy and area under the receiver operating characteristic curve over the predictive probability,
we show that our method is less susceptible to making overconfident predictions, especially for the
minority class in imbalanced datasets. Finally, we demonstrate how uncertainty information derived
by the model can inform risk factor analysis towards model interpretability.
1 Introduction
The application of deep learning to medicine has been growing over recent years. Much of research in this field has
been focusing on estimating and improving “point predictions” in form of personalised risk scores for a given medical
event in one’s future, as for instance reported in innovative deep learning models such as Deepr [1], RETAIN [2] and
Doctor AI [3]. However, point predictions – quite naturally – are prone to overconfidence. Considering the significant
consequences of decision making in clinical practice that is guided by model predictions, quantifying the uncertainty of
predictions is proving to be a key step in putting these models to practice in medicine.
In the last several years, a new subfield of deep learning, called probabilistic deep learning, has drawn wide interest
to provide probabilistic predictions and uncertainty estimations at the same time. The most promising methods are
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Bayesian deep learning (BDL) [4, 5] and sparse Gaussian processes (GP) [6, 7]. In BDL, by placing a distribution
over each of the model weights instead of treating them as point values, the uncertainty of the weights can be passed
layer by layer to eventually estimate the uncertainty in the predictions. However, this approach usually requires a
compromise between model complexity and expressiveness of variational distributions. On the contrary, the GP model,
as a non-parametric model, is more flexible and expressive than BDL. This advantage comes, however, at the expense of
the need to store and process the data points for the covariance matrix. This usually takes cubic time O(n3) to calculate
the inversion and determinant of the covariance matrix for inference [8] and becomes a challenge when working with
large-scale datasets. The state-of-the-art solution to this challenge is to use a small number of pseudo-points, i.e.,
inducing points, to approximate the data points. This enables the covariance matrix to be approximated by a lower-rank
representation [9, 10]. Since the entire dataset is summarised by a small number of inducing points, this method is
called sparse GP. [11] upgraded this framework to be more flexible and scalable by implementing a deep architecture
beneath the kernel function as a feature extractor, which is known as deep kernel learning (DKL). Although the deep
architecture provides a significant boost in representational power, the framework can only capture the uncertainty in
the higher-level latent space (after the deep architecture). This results in a lack of interpretability, and failure to capture
the uncertainty in the deep architecture.
The core idea of this paper is to combine the strengths of both frameworks by merging the BDL concept with the DKL
framework. We expect that this could retain the expressiveness from GP while capturing the uncertainty during feature
extraction, leading to: (1) a probabilistic feature representation for more robust inducing points and kernel training;
and (2) a more comprehensive uncertainty estimation. Additionally, we investigate how the uncertainty information
naturally contained in the Bayesian components can contribute to interpretable risk factor analysis in medical research.
2 Background
2.1 Task description
Figure 1: The axis represents the time; medical records before "now" are used to predict the incidence of a condition in
the following six months; the medical records include multiple visits, and each visit has one or more diagnoses and
medications; the interval between two visits represents the time duration between them.
For this study, we explored a risk model for detecting the first incidence of three common chronic diseases, namely,
heart failure (HF), diabetes and depression, using structured electronic health record (EHR) from the Clinical Practice
Research Datalink (CPRD) [12, 13, 14]. We used diagnoses (ICD-10 [15]), medications (British National Formulary
code [16]), event date (time stamp for each diagnosis and medication) and date of birth as historical medical trajectory
to predict whether the first incidence of aforementioned conditions would be diagnosed in the following six months for
a patient, and the conditions are treated as separate prediction tasks. The design is summarised in Figure 1, and the
ICD-codes for HF, diabetes, and depression are listed in Table S1,S2,S3, in Supplementary A. They were taken from
previous publications [17, 18].
2.2 Data source and cohort selection
CPRD is one of the most comprehensive de-identified longitudinal population-based EHR datasets. It contains primary
care data collected from a network of general practitioner practices across the UK, and it is also linked to Hospital
Episode Statistics [19] and other health and area-based administrative databases. The data encompass 42 million
patients, including 13 million currently registered patients. The patients included are nationally representative in terms
of age, sex, and ethnicity [14].
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For this study, we set up a two-stage pipeline (A and B) for patient selection. Figure S1 in Supplementary B illustrates the
procedures and the number of patients kept within each step. Stage A was a general data linkage step to select patients
that met the minimum requirements for the study. This dataset was used for general unsupervised pre-training [20, 21].
Stage B was designed for generating samples for the individual prediction tasks. Firstly, for a patient who had the
pre-defined condition, records were formatted as in Figure 1, where all medical records before the first incidence of the
condition were included as history records. For a patient who did not have the pre-defined condition, we randomly
selected a time point to separate the records into history records and marked the patient as a negative sample. For all
negative patients, we made sure that they had more than six months medical records after the selected time point to
guarantee each of them was an absolute negative sample. Therefore, avoiding any assumption for the unseen future.
The patient selection rules in stage B that kept patients who had enough records to be trained, eventually led to 788,880
(8.3% positive samples), 913,799 (11.3% positive samples) and 1,453,012 (16% positive samples) patients for HF,
diabetes and depression, respectively. We refer to the datasets from stages A and B as datasets A and B, respectively.
3 Related work
This section reviews the necessary concepts and related works.
3.1 BEHRT
BEHRT [22] is a recently developed model that applied the concept of self-attention transformer from natural language
processing to EHRs. BEHRT took advantage of the self-attention mechanism and sequential format of EHRs in a
way that maximally preserves the EHR-like structure. The feature structure is shown in Figure 2, with each encounter
corresponding to the so-called "token" in transformers [23]. In this illustration, there are four embedding matrices for
diagnoses and medications, age, segmentation and position separately. BEHRT uses the summation of the embeddings
to represent each encounter. Recent work has shown that BEHRT outperform other deep learning models for disease
prediction based in the context of complex large-scale sequential EHR. More detailed information can be found in [22].
Figure 2: Four feature layers: clinical diagnoses and medications, age, segmentation and positional code; each visit
could have multiple encounters and each encounter is a representation of multiple feature layers; summation of all
embeddings are used for encounter representation.
3.2 Gaussian processes
GPs are expressive non-parametric models [24]. We only consider regression at this stage, but they can be easily used
for binary classification tasks by wrapping a logistic regression [25]. If we have observed training data,D = {xi, yi}Ni=1
with xi ∈ χ and yi ∈ R, our target is to predict output y∗ for new inputs x∗. GPs usually place a GP prior over the
latent function as f ∼ GP(v(·), k(·, ·)), where v : χ→ R is the mean function, and it is often taken as zero. The kernel
function k : χ× χ→ R controls the smoothness of GPs. A likelihood is then used to relate the latent function to the
observed data through some noise, which is represented as yi = f(xi) + i, i ∼ N (0, σ2n). In the end, we use the
posterior for predictions and the marginal likelihood for selecting hyperparameters, which is shown in Equation 1:
log p(y) = −1
2
yTK−1n y −
1
2
log|Kn| − N
2
log(2pi) (1)
, whereKn = Kff + σ2nI and |Kff|i,j = k(xi, xj).
3.3 Whitened-GPs
Because of the complexity of calculating the determinant and inverse, many approaches have been proposed to
approximateKff with a lower rank matrix [7]. One popular approach is posterior approximation through variational
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free energy proposed by [9]. The method suggests to optimise the evidence lower bound to minimise the KL divergence
between posterior and variational distribution. Therefore, it directly approximats the posterior with a relatively small
number of inducing points, and eventually simplifies the calculation. The evidence lower bound:
LSGP =− 1
2
yTQ−1n y −
1
2
log|Qn| − N
2
log(2pi)
− t
2σ2n
(2)
, whereQn = Qff +σ2nI ,Qff = K
T
ufK
−1
uu Kuf, t = Tr(Kff−Qff), [Kuf]m,i = k(zm, xi) and [Kuu]m,i = k(um, ui),
U = {um}Mm=1 represents inducing points; and SGP represents sparse GP.
3.4 KISS-GPs
Besides posterior approximation, [26] proposed a structured kernel interpolation framework to produce a more scalable
kernel approximation, named KISS-GP. This method combines structure exploiting approaches, inducing points and
sparse interpolation to further reduce the inference time cost and storage costs from O(m2n+m3) and O(mn+m2),
respectively, for whitened-GPs to O(n). Additionally, it provides a more accurate and a scalable inference and more
flexible kernel learning on large datasets. The main idea of this method is to impose the grid constraint on the inducing
points. Therefore, the kernel matrixKuu admits the Kronecker structure for d > 1, where d represents the dimension of
the grid, The kernel could then be decomposed to a Kronecker product k(ui, uj) =
∏d
t=1 k(u
t
i, u
t
j). Additionally, if
d = 1, the kernel is then a Toeplitz covariance matrix and can be calculated as k(ui, uj) = k(ui − uj). For the cross
kernel matrixKuf, it is approximated, for example, by a local linear interpolation with adjacent grid inducing points; an
example is as shown in Equation 3:
k(xi, uj) ≈ wik(ua, uj) + (1− wi)k(ub, uj) (3)
, where ua and ub are two inducing points on the grid that are closest to xi, and wi is an interpolation weight that
represents the distance to the inducing point. Eventually, the Qff matrix in Equation 2 can be approximated as
Equation 4:
Qff ≈W TufK−1uu W uf (4)
3.5 Deep kernel learning
In addition to sparse GP, [11] moved one step further and proposed to embed deep neural networks (DNNs) with GPs to
learn more flexible representations. The kernel function transforms from k(xi, xj |θ) to k(g(xi,w), g(xj ,w)|θ,w),
where θ are the kernel hyperparameters, g(·) is a non-linear DNN, and w are the parametrised weights of the network.
Therefore, the DNN acts as a feature extractor to represent samples as latent vectors, and GPs can make inferences
based on the learned latent features.
3.6 Variational inference for Bayesian deep learning
Bayesian deep learning is another approach to implement a probabilistic model for uncertainty estimation. Instead of
using point weights as deterministic DNNs, it places distributions over all model parameters [27], and the predictive
distribution can be estimated by marginalising the parameters [28, 29]; this is shown as Equation 5.
p(y∗|x∗,D) =
∫
Ω
p(y∗|x∗,w)p(w|D)dw (5)
, where w ∈ Ω represents parametrised weights. However, the posterior p(w|D) is usually intractable in neural
networks. In order to retrieve it, [30] proposed to approximate the posterior by optimising the evidence lower bound to
minimise the KL divergence between variational distribution and posterior, which is shown in Equation 6:
LBDL =
∫
Ω
qγ(w)log(p(D|w))dw
−KL(qγ(w)||p(w))
(6)
, where qγ represents the variational distribution, which is parameterised by γ. Afterwards, p(w|D) in Equation 5 can
be replaced by qγ(w) for inference.
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3.7 Challenges in uncertainty evaluation
In recent research, high test log-likelihood has commonly been used to indicate the model’s credibility to capture the
true posterior [31, 32]. However, [33] did an experiment by constructing the "ground-truth" posterior and posterior
predictive distribution by Hamiltonian Monte Carlo. They compared the approximated posteriors from inference
methods such as probabilistic backpropagation, matrix-variate Gaussian and Bayes by hypernet with the "ground-truth".
Even though the approximate posteriors incorrectly had a lower variance, they still yielded similar test log-likelihood as
the ground-truth. Therefore, we argue that the test log-likelihood would be more meaningful to evaluate the posterior
mean rather than the uncertainty (variance), and it is not a reliable criterium for determining how well an approximate
posterior aligns with the true posterior.
4 Proposed methods
4.1 Deep Bayesian Gaussian processes
In this section, we present the approach of our work, which combines the DKL with Bayesian inference for a more robust
uncertainty estimation, and we refer to this architecture as deep Bayesian Gaussian processes (DBGPs). Additionally,
we show how to learn the properties of these kernels as part of a scalable GP. We start with the kernel and inference of a
GP, and the kernel hyperparameter θ is ignored for the following parts to simplify the illustration. As for Equation 3,
the base kernel is shown as k(xi, xj); thus, the inference stage can be represented as:
p(f∗) =
∫
p(f∗|x∗,fm)p(fm)dfm (7)
p(y∗) =
∫
p(y∗|f∗)p(f∗)df∗ (8)
, where fm represents the latent prior from observed points or inducing points for GPs and sparse GPs, respectively.
For DKL, the kernel is transformed to k(g(xi,w); g(xj ,w)), such a kernel function is used to measure the similarity
between two latent representations extracted by a DNN. Accordingly, the inference for p(f∗) is changed to Equation 9,
while p(y∗) remains the same.
p(f∗) =
∫
p(f∗|x∗,w,fm)p(fm)dfm (9)
In addition to the DKL, DBGP replaces the weights of the DNN as distributions. Therefore, besides marginalising the
fm, we also need to marginalise the weights for the inference. The p(f
∗) for DBGP is now transformed as follows:
p(f∗) =
∫
Ω
∫
p(f∗|x∗,w,fm)p(w|D)p(fm)dfmdw (10)
Since the posterior p(w|D) is usually intractable, we use a variational distribution qγ(w) parametrised by γ to
approximate it and then jointly train all the kernel hyperparameters {θ,γ} together by optimising the evidence lower
bound as Equation 11, and update the hyperparameters through chain rule in Equations 12 and 13:
LDBGP = LSGP −KL(qγ(w)||p(w)) (11)
∂LDBGP
∂θ
=
∂LDBGP
∂LSGP
∂LSGP
∂K
∂K
∂θ
(12)
∂LDBGP
∂γ
=
∂LDBGP
∂LSGP
∂LSGP
∂K
∂K
∂qγ(w)
∂qγ(w)
∂γ
− ∂LDBGP
∂KL
∂KL
qγ(w)
∂qγ(w)
∂γ
(13)
Figure 3 provides an illustration of the potential difference between DKL and DBGP in terms of the predictive
coverage. Unlike DKL, which maps the raw features into a fixed latent representation (x in the figure) by a deep
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architecture, where uncertainty estimation of f(x) completely comes from the GP, DBGP is able to capture the
uncertainty hierarchically. The uncertainty captured by the deep Bayesian architecture is firstly reflected on the
uncertainty in the latent representation (x in the figure). Afterwards, such uncertainty in the latent representation moves
forward to the GP. Eventually, the predictive uncertainty represents the uncertainty in both x and f(x) dimensions,
which is more comprehensive and shows a wider predictive coverage.
Figure 3: Predictive distribution for DKL and DBGP; the yellow area indicates the potential area for the predicted
values.
4.2 Experiments
Figure 4: Model architecture; the embedding and the pooling are also included in BEHRT; the pooling layer only
extracts the latent representation of the first encounter (time step) for classification.
In our experiments, the model includes a feature extractor (BEHRT) and a classifier, as shown in Figure 4. We compare
the proposed DBGP with DBL and DKL. The definitions of different architectures are listed below:
Bayesian Embedding + KISS-GP (DBGP): The proposed DBGP framework with a Bayesian BEHRT as a feature
extractor, in which the embedding parameters are stochastic, and a KISS-GP as the classifier; all the other parameters
are deterministic.
Bayesian Embeddings (BE): A Bayesian BEHRT in which the embedding parameters are stochastic, and all the other
parameters are deterministic.
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Bayesian Output (BO): A Bayesian BEHRT in which the classifier parameters are stochastic, and all the other
parameters are deterministic.
Bayesian Embedding + Output (BE + BO): A Bayesian BEHRT in which the embedding and classifier parameters
are stochastic, and all other parameters are deterministic.
Whitened-GP: A BEHRT model with a whitened-GP as the classifier, all the other parameters are deterministic.
KISS-GP: A BERHT model with a KISS-GP as the classifier, all the other parameters are deterministic.
[34] indicates that for BDL, models with Bayesian embedding and Bayesian output usually work better than fully
Bayesian models, so we mainly investigate the Bayesian model with stochastic embedding and output. Additionally,
all the Bayesian components are formulated with a mean field distribution with zero mean for the prior, and all GP
components are implemented with a multivariate distribution with zero mean and identity covariance matrix for the
prior. The details of the other model parameters can be found in Table S4 in Supplementary C, which is selected by
Bayesian hyperparameter optimisation.
4.3 Evaluation methods
In this work, Monte Carlo [28] was used for all probabilistic models to estimate the predictive distribution, and we
evaluated the model performance from three perspectives: generalisation, ability of rejecting overconfident predictions
and uncertainty estimation. For generalisation, we evaluated the area under the receiver operating characteristics
(AUROC) curve and average precision (AP) [35]; both of them were calculated based on the mean predictive probability.
As for the ability of rejecting overconfident predictions, we evaluated the accuracy and AUROC as a function of the mean
predictive probability. In medicine, it is highly desirable to avoid overconfident and incorrect predictions. Therefore,
it is more useful to evaluate the model performance for predictions above a user-specified threshold. One tends to
trust the predictions more when the confidence is high, and resorts to a different resolution when the prediction is not
confident. Thus, the better rejection ability can be directly reflected by having a higher performance for high-confident
predictions. For uncertainty estimation, we propose (1) to treat the uncertainty measurement for classification differently
by measuring the difference between the variance of true positives and the variance of false positives. We would
intuitively expect that the variance of true positives is distinguishably lower than the one of false positives. On the
contrary, if the variance for both true positives and false positives are similar, we would say the model cannot provide a
meaningful uncertainty estimation; (2) for imbalanced datasets, because the model is usually biased by the majority
class, we would intuitively expect the model to have a higher uncertainty for the minority classes. Therefore, these two
criteria are used as indication of the quality of the uncertainty estimation. To quantify the performance of the former
criteria, we propose to calculate the Kullback-Leibler (KL) divergence between the uncertainty (standard deviation
(std)) distribution of true positives and the uncertainty (std) distribution of false positives as Equation 14, and the larger
the value is, the better the performance is. We can assume that both distributions are Gaussian distributions because of
the central limit theorem [36].
DIV = KL(p(FP )||p(TP )) (14)
Here KL represents the KL divergence, p(FP ) is the distribution of false positives’ uncertainty, and p(TP ) is the
distribution of true positives’ uncertainty.
4.4 Uncertainty analyses in embeddings
In addition to the model performance evaluation, for models with Bayesian embeddings, we explore the linkage
between embedding uncertainty and relative risk associations. For diagnoses or medications with high uncertainty in the
embeddings, we assume they would contribute more uncertainty to the latent representations as well as the predictions.
Therefore, higher uncertainty in the embedding indicates an unclear association between a disease or a medication and
the target disease, otherwise, the association would be more certain even though the magnitude of the association is
strong or weak. We used entropy [37] to indicate the embedding uncertainty, and a detailed discussion will be covered
in Section 5.4.
5 Results
We used the Monte Carlo method to sample each patient’s prediction 30 times as an estimation of the predictive
distribution for all analyses within this section. For comparison, we repeated the analysis with 60 samples and found no
material difference in the prediction (Supplementary E).
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5.1 Generalisation performance
Table 1: Prediction performance: metrics are calculated based on the mean predictive probability of 30 samples in the
validation set.
HF DIABETES DEPRESSION
MODEL A B A B A B
DBGP 0.941 0.625 0.834 0.533 0.776 0.416
WHITENED GP 0.945 0.645 0.835 0.540 0.782 0.432
KISS-GP 0.945 0.650 0.836 0.536 0.782 0.433
BE 0.942 0.630 0.831 0.529 0.774 0.409
BO 0.932 0.644 0.824 0.524 0.767 0.426
BE+BO 0.941 0.628 0.835 0.537 0.778 0.419
A: AUROC, B: AVERAGE PRECISION
We compared the performance for generalisation of aforementioned six probabilistic models. In our experiments, we
split each dataset (HF, diabetes and depression) into 70% training set and 30% validation set. Before training for a
specific prediction task, we pre-trained the original deterministic BEHRT model on the dataset A, which is explained
in Section 2.2, based on an unsupervised masked language model task [23]. Then, to fine-tune the model for the
prediction task, we initialised the deterministic parameters with the pre-trained model parameters, and for all stochastic
components, we used the pre-trained parameters as the mean of their variational distribution. Since the classifier was
not a part of the masked language model training task, all the parameters within the classifier were randomly initialised.
Table 1 demonstrates the performance for the marginalised prediction performance of each probabilistic model. It
shows that all implemented probabilistic models have a comparable performance in terms of generalisation. The result
is expected, because all models share the same fundamental BEHRT model.
5.2 Accuracy and AUROC as a function of confidence
We re-used the results from the experiments in the previous section to evaluate the ability of rejecting overconfident
predictions based on the mean predictive probability.
For the accuracy vs confidence curve, we treated the prediction as a two class classification task, with the mean
prediction p(y = k|x), where k represents the kth class, which is 2 in total in our case (binary classification). We
defined the predicted label as yˆ = argmaxkp(y = k|x) and the confidence as p(y = yˆ|x) = maxkp(y = k|x). The
performance of accuracy for patients with confidence above different thresholds is shown in Figure 5. A1, B1 and C1
are the evaluations for HF, diabetes and depression respectively. Because we only considered samples with confidence
above each threshold, we would expect a rise in accuracy with increase in confidence thresholds. The figures show
that the GP-based methods outperform the BDL models. Furthermore, the proposed method DBGP shows a better
performance than the other models, especially for the high-confident predictions.
Additionally, unlike the measurement for the accuracy vs confidence curve, to know more details about the model
performance over different predictive probabilities, we used the mean predictive probability carried out by the models to
evaluate the performance over the predictive confidence in terms of AUROC. The results are shown in A2, B2 and C2 in
Figure 5. These figures illustrate that the proposed DBGP model has a better AUROC over the predictive confidence in
general. Furthermore, it shows more robust predictions for the minority (positive) class. Instead of giving overconfident
predictions, DBGP shows a better capability of penalising highly confident predictions, and such effects become more
significant when the model prediction performance drops (among HF, diabetes and depression prediction).
5.3 Uncertainty estimation
In this experiment, we evaluated the performance of uncertainty estimation for models based on the aforementioned
two criteria in Section 4.3: (1) predictions should intuitively have a higher uncertainty for the minority class than the
majority class in the imbalanced dataset; and (2) the true positive predictions should have less uncertainty than the false
positive predictions.
To evaluate the uncertainty across different predictive probabilities, instead of using the mean predictive probability, we
calculated the empirical frequency across the predictive probability for each set of samples. Therefore, we can estimate
the uncertainty of predictions over predictive probabilities. The results are shown in Figure 6.
The figure shows the consistency with the previous results in Figure 5 that the proposed method DBGP has a better
rejection capability for the biased positive predictions, and the rejection becomes significant when the generalisation
8
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Figure 5: Accuracy and AUROC vs confidence curves; A: Heart failure, B: Diabetes, C: Depression; the x-axis
represents the mean predictive probability, and the y-axis represents the accuracy or AUROC.
performance drops. Additionally, it also indicates that GP-based methods are better at capturing uncertainties for
positive predictions in imbalanced datasets than the BDL-based models. For BDL-based models, we can observe that
for rhe HF prediction task, even though the prediction performance in terms of average precision is relatively poor,
they are still very certain for those high-confidence positive predictions. The uncertainty only starts to show when the
model performance is extremely poor, as shown in depression prediction task. In contrast, DBGP shows the capability
of capturing the uncertainty for the minority class, and also illustrates a better calibration for positive predictions.
Additionally, to evaluate the uncertainty difference between true positives and false positives, we represented each
patient with mean predictive probability and corresponding std calculated from samples from predictive distributions.
Furthermore, we considered samples with predictive probability higher than 0.5 to be predicted as positives and
predictive probability less than 0.5 to be predicted as negatives. Figure 7 uses the boxplot to show the distribution of
std for all positive predictions and negative predictions. It shows that the Bayesian-embedding-based methods have
better a capability to capture the uncertainty to distinguish the true positives and false positives, true negatives and false
negatives (for the convenience of description, we also consider true negative as true positive and false negative as false
positive). On the contrary, the GP-based methods either provide an indistinguishable uncertainty estimation for true
positives and false positives, or provide uncertainty estimations that seem incorrect, as shown by the uncertainty for true
positives being even higher than the false positives. Therefore, for those models that show the correct trend, we propose
to calculate the divergence between the distribution of true positives and the distribution of false positives to quantify
the quality of distinguishability, as explained in Section 4.3. The results are shown in Table 2.
Table 2 indicates that the uncertainty estimation is ambiguous for true positives and false positives if the model prediction
performance is relatively poor, such as for depression. As the prediction performance improves (diabetes), the Bayesian
methods become slightly better than DBGP. However, when the prediction performance reaches a certain level (HF),
DBGP equally performs as well as the deep Bayesian models.
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Figure 6: Calibration curve; the x and the y axis represent the predictive probability and the fraction of positive
predictions respectively; A: heart failure, B: diabetes, C: depression
Table 2: Uncertainty divergence (DIV): DIV calculates the KL divergence between the std distributions of false positive
and true positive predictions.
HF DIABETES DEPRESSION
MODEL P N P N P N
DBGP 0.330 0.867 0.105 0.146 0.009 0.279
BE 0.298 0.995 0.585 0.286 0.009 0.250
BE+BO 0.360 0.224 0.427 0.311 0.009 0.158
P: POSITIVE PREDICTION, N: NEGATIVE PREDICTION
5.4 Embedding analysis
The DBGP framework not only improves the ability of uncertainty estimation, but also brings a certain level of
interpretability to the underlying deep architecture. In this section, we analysed the uncertainty of Bayesian embeddings
by measuring its entropy for the DBGP model to understand how the embedding affects the uncertainty in the latent
representation. Entropy is a commonly used metric to quantify the uncertainty of a probability distribution [37].
Because we only imposed the uncertainty to the embedding layer, all the uncertainty of the latent representation came
from the embedding. Intuitively, a higher uncertainty of the embedding contributes more to the uncertainty of the latent
representation. Therefore, if an embedding has a high uncertainty, it can mean a diagnosis or medication has more
complex contextual information, and its association with the prediction is more unclear. In this case, such information
can give us guidance to: (1) whether a causal or direct association is more likely to be included in the low uncertainty
(low entropy) group; (2) whether the joint association has a higher chance to be included in the high uncertainty (high
entropy) group. We list the diagnoses and medications with top 10 lowest entropy from HF in Table 3, more information
about entropy values for diabetes and depression can be found in Table S5 in Supplementary D and the Table S6 of
Supplementary D illustrates the diagnoses and medications with highest entropy.
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Figure 7: Distribution of std for positive and negative predictions; A, B and C represent the heart failure, diabetes and
depression prediction tasks, respectively; 1 represents samples with mean predictive probability larger than 0.5 (positive
prediction), and 2 represents samples with mean predictive probability less than 0.5 (negative prediction), for instance:
A1 means positive prediction for HF prediction task; orange and blue represent samples with label positive and negative,
respectively.
Table 3: Entropy measurement for diagnoses and medications; top 10 lowest entropy diagnoses and medications
for heart failure. The entropy is calculated by the summation of the entropy of the distribution over all embedding
dimensions.
ENTROPY DESCRIPTION
-236.14 DIURETICS
-235.67 ACUTE MYOCARDIAL INFARCTION, UNSPECI-
FIED
-235.43 UNSPECIFIED ACUTE LOWER RESPIRATORY
INFECTION
-235.17 OTHER ILL-DEFINED HEART DISEASES
-235.12 ANTIPLATELET DRUGS
-235.08 CHRONIC OBSTRUCTIVE PULMONARY DIS-
EASE WITH (ACUTE) EXACERBATION
-234.97 CHRONIC OBSTRUCTIVE PULMONARY DIS-
EASE, UNSPECIFIED
-234.95 TORTICOLLIS
-234.90 CELLULITIS AND ACUTE LYMPHANGITIS OF
OTHER PARTS OF LIMB
-234.68 TYPE 2 DIABETES MELLITUS WITH CIRCULA-
TORY COMPLICATIONS
Table 3 shows that most of the low entropy diagnoses and medications are closely associated to HF, and similar patterns
can also be found in diabetes and depression. This method suggest a link between uncertainty and risk factor analyses
and can potentially be used to further assist the model interpretability and guide future causality analyses.
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6 Discussion
In this paper, we have proposed a mixed architecture named DBGP. It combines the strengths from both GPs and BDL,
showing strong performance for rejecting overconfident predictions and providing a more robust uncertainty estimation.
From the experiments in this paper, we have noticed that our methods can provide more reasonable estimation for the
true positive and false positive predictions. Additionally, it could indicate the insufficiency and the robustness for biased
predictions in the imbalanced dataset, whereas GPs and BDL can only show promising results for one of those two
aspects. Furthermore, we investigated the associations between uncertainty and risk factors, and the results showed
strong evidence for the relation. Therefore, an interesting topic for future work lies in an interpretability and causality
analysis.
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Supplementary
A Condition description
Table S1: Heart failure conditions
ICD-10 Description
I09.9 Rheumatic heart disease, unspecified
I11.0 Hypertensive heart disease with (conges-
tive) heart failure
I13.0 Hypertensive heart and renal disease with
(congestive) heart failure
I13.2 Hypertensive heart and chronic kidney dis-
ease with heart failure and with stage 5
chronic kidney disease, or end stage renal
disease
I25.5 Ischaemic cardiomyopathy
I27.9 Pulmonary heart disease, unspecified
I38 Endocarditis, valve unspecified
I42.0 Dilated cardiomyopathy
I42.1 Obstructive hypertrophic cardiomyopathy
I42.2 Other hypertrophic cardiomyopathy
I42.6 Alcoholic cardiomyopathy
I42.8 Other cardiomyopathies
I42.9 Cardiomyopathy, unspecified
I50.0 Congestive heart failure
I50.1 Left ventricular failure
I50.2 Systolic (congestive) heart failure
I50.3 Diastolic (congestive) heart failure
I50.8 Other heart failure
I50.9 Heart failure, unspecified
Table S2: Diabetes conditions
ICD-10 Description
E10.0-E10.9 Type 1 diabetes mellitus
E11.0-E11.9 Type 2 diabetes mellitus
E12.0-E12.9 Malnutrition-related diabetes mellitus
E13.0-E13.9 Other specified diabetes mellitus
E14.0-E14.9 Unspecified diabetes mellitus
O24.2 Pre-existing malnutrition-related diabetes
mellitus
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Table S3: Depression conditions
ICD-10 Description
F32.0 Mild depressive episode
F32.1 Moderate depressive episode
F32.2 Severe depressive episode without psy-
chotic symptoms
F32.3 Severe depressive episode with psychotic
symptoms
F32.8 Other depressive episodes
F32.9 Depressive episode, unspecified
F33.0 Recurrent depressive disorder, current
episode mild
F33.1 Recurrent depressive disorder, current
episode mild
F33.2 Recurrent depressive disorder, current
episode severe without psychotic symptoms
F33.3 Recurrent depressive disorder, current
episode severe with psychotic symptoms
F33.4 Recurrent depressive disorder, currently in
remission
F33.8 Other recurrent depressive disorders
F33.9 Recurrent depressive disorder, unspecified
F34.1 Dysthymia
F38.1 Other recurrent mood [affective] disorders
B Cohort selection
Figure S1: Patient selection; stage A illustrates the data cleaning pipeline from raw CPRD dataset to the dataset for
model pre-training; and Stage B is used for patient selection for the incidence prediction tasks; the number of patients
been kept in each step is represented as n.
C Model configuration
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Table S4: Model parameters
All
Maximum Sequence Length 256
Hidden Size 150
Number of Hidden Layers 4
Number of Attention Heads 6
Intermediate Size 108
Hidden Dropout 0.29
BE/BO/BE+BO Others
Pool Layer Size 150 24
BE/DBGP BO/BE+BO
Embedding Prior Std 0.374 0.374
Output Prior Std - 1
D Entropy measurement
Table S5: Entropy measurement for diagnoses and medications; top 10 lowest entropy diagnoses and medications
for diabetes and depression. Entropy is calculated by the summation of entropy of distribution over all embedding
dimensions.
ENTROPY DESCRIPTION
DIABETES
-230.52 DRUGS USED IN DIABETES
-230.28 DETECTION STRIPS, URINE FOR GLYCO-
SURIA
-229.18 UNSPECIFIED DIABETES MELLITUS
-229.16 HYPOGLYCEMIA, UNSPECIFIED
-229.00 OBESITY, UNSPECIFIED
-228.42 ESSENTIAL (PRIMARY) HYPERTENSION
-227.24 POSITIVE INOTROPIC DRUGS
-226.98 LIPID-REGULATING DRUGS
-226.96 CHRONIC TUBULO-INTERSTITIAL NEPHRITIS,
UNSPECIFIED
-226.77 SEX HORMONES
DEPRESSION
-229.68 ANTIDEPRESSANT DRUGS
-221.35 ANXIETY DISORDER, UNSPECIFIED
-220.69 INFLUENZA DUE TO UNIDENTIFIED IN-
FLUENZA VIRUS WITH OTHER RESPIRATORY
MANIFESTATIONS
-219.65 DRUGS USED IN PSYCHOSES AND
REL.DISORDERS
-219.58 ANALGESICS
-219.36 HYPNOTICS AND ANXIOLYTICS
-219.24 LAXATIVES
-219.15 LOW BACK PAIN
-219.13 GENERAL ANAESTHESIA/HYPNOTICS AND
ANXIOLYTICS
-219.09 DYSPEP AND GASTRO-OESOPHAGEAL RE-
FLUX DISEASE
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Table S6: Entropy measurement for diagnoses and medications; top 10 highest entropy diagnoses and medications
for heart failure, diabetes and depression. Entropy is calculated by the summation of entropy of distribution over all
embedding dimensions.
ENTROPY DESCRIPTION
HEART FAILURE
-226.61 TRAUMATIC SUBDURAL HEMORRHAGE
-227.24 PERITONSILLAR ABSCESS
-227.39 COUGH SUPPRESSANTS/OPIOID ANAL-
GESICS/DRUGS USED IN SUBSTANCE
DEPENDENCE - OPIOID DEPENDENCE
-227.61 MALIGNANT NEOPLASM OF MAIN BRONCHUS
-227.78 OTHER SPECIFIED NONINFLAMMATORY DIS-
ORDERS OF UTERUS
-227.99 GLAUCOMA SUSPECT
-228.07 UROSTOMY BAG
-228.13 SYNOVITIS AND TENOSYNOVITIS, UNSPECI-
FIED
-228.25 SUBJECTIVE VISUAL DISTURBANCES
-228.27 DELIVERY BY ELECTIVE CAESAREAN SEC-
TION
DIABETES
-218.64 RETAINED PLACENTA WITHOUT HEMOR-
RHAGE
-218.64 DISEASE OF STOMACH AND DUODENUM, UN-
SPECIFIED
-218.90 INTRADUCTAL CARCINOMA IN SITU OF
BREAST
-218.97 ACUTE NONINFECTIVE OTITIS EXTERNA
-219.39 NONTOXIC GOITER, UNSPECIFIED
-219.49 MALIGNANT NEOPLASM OF UNSPECIFIED
OVARY
-219.54 DRUGS USED IN RHEUMATIC DISEASES AND
GOUT/PREPARATIONS FOR ECZEMA AND
PSORIASIS
-219.58 LATERAL EPICONDYLITIS
-219.71 DELUSIONAL DISORDERS
-219.97 DORSOPATHY, UNSPECIFIED
DEPRESSION
-210.28 OTHER SPECIFIED DISORDERS OF SYNOVIUM
AND TENDON
-210.79 ANTIHIST, HYPOSENSIT AND ALLERGIC
EMERGEN/COUGH PREPARATIONS
-210.81 VIRAL WART, UNSPECIFIED
-210.84 OTHER SPECIFIED VIRAL INFECTIONS CHAR-
ACTERIZED BY SKIN AND MUCOUS MEM-
BRANE LESIONS
-210.95 CANDIDIASIS OF SKIN AND NAIL
-211.13 MALIGNANT NEOPLASM OF HEAD OF PAN-
CREAS
-211.16 MUMPS WITHOUT COMPLICATION
-211.24 DYSTHYMIA
-211.25 ACUTE POSTHEMORRHAGIC ANEMIA
-211.25 FRACTURE OF UPPER END OF TIBIA
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Table S7: Prediction performance: N = 60 samples are sampled from the predictive distribution of each patient in the
validation set for all probabilistic models, and both metrics are calculated based on the mean predictive probability of
N samples.
HF DIABETES DEPRESSION
MODEL A B A B A B
WHITENED GP 0.945 0.646 0.835 0.540 0.782 0.434
KISS-GP 0.945 0.650 0.836 0.536 0.782 0.433
BE 0.942 0.631 0.831 0.529 0.774 0.410
DBGP 0.942 0.627 0.834 0.534 0.776 0.416
BO 0.935 0.648 0.828 0.526 0.772 0.428
BE+BO 0.941 0.629 0.836 0.537 0.779 0.420
A: AUROC, B: AVERAGE PRECISION
E Results for 60 times of sampling from predictive distribution
E.1 Generalisation performance
E.2 Accuracy and AUROC as a function of confidence
Figure S2: Accuracy and AUROC vs Confidence curves; N=60 samples are sampled from the predictive distribution of
each patient, and metrics are calculated based on the mean predictive probability of N samples; A: Heart failure, B:
Diabetes, C: Depression; x-axis represents the mean predictive probability and y-axis represents accuracy or auroc.
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E.3 Uncertainty estimation
Figure S3: Calibration curve; x-axis represents the predictive probability and y-axis represents the empirical frequency;
N=60 samples are sampled from the predictive distribution of each patient; A: heart failure, B: diabetes, C: depression.
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Figure S4: Distribution of std for positive and negative predictions; A, B and C represent heart failure, diabetes and
depression prediction tasks respectively; 1 represents samples with mean predictive probability larger than 0.5 (positive
prediction), and 2 represents samples with mean predictive probability less than 0.5 (negative prediction), for instance:
A1 means positive prediction for heart failure prediction task; orange represents samples with label positive, and blue
represents samples with label negative; the std for each patient is calculated from 60 times of sampling of a patient’s
predictive distribution.
F population statistics for accuracy analysis
Figure 5 shows the accuracy over different confidence threshold, here we present more details about the number of
patient above each threshold in Figure S5.
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Figure S5: Number of patients above certain confidence threshold.
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